Sionna Therapeutics
Tracked across 2 events · 30 articles · First seen Aug 10, 2026 · Last active Sep 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
On August 10, 2026, Sionna Therapeutics announced that its Phase 2a PreciSION CF trial of SION-719, an investigational cystic fibrosis treatment, failed to achieve its key activity endpoint of sweat chloride reduction when added to…
Impact: Sionna Therapeutics is the central entity; its Phase 2a trial failure caused a 91% stock price collapse and triggered securities investigations. The company faces potential legal claims and reputational damage.
Aug 12, 2026 · 24 articles
Business
Impact: Sionna Therapeutics is mentioned as Ridloff's current employer, but is not directly affected by this event.
Aug 10, 2026 · 6 articles
100
Sionna Therapeutics reported failed trialSionna Therapeutics Phase...
100
Sionna Therapeutics lost 90% market valueSionna Therapeutics Phase...
80
Levi & Korsinsky launched investigation Sionna TherapeuticsSionna Therapeutics Phase...
80
Robbins Geller Rudman & Dowd LLP launched investigation Sionna TherapeuticsSionna Therapeutics Phase...
80
Pomerantz LLP launched investigation Sionna TherapeuticsSionna Therapeutics Phase...
ERGEN INTELLIGENCE
Track Sionna Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard